Derek Archila
Stock Analyst at Wells Fargo
(3.83)
# 649
Out of 4,479 analysts
127
Total ratings
41.84%
Success rate
10.74%
Average return
Main Sectors:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $478 → $542 | $435.49 | +24.46% | 7 | Jun 24, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Equal-Weight | $29 → $9 | $3.57 | +152.10% | 3 | Jun 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $57 → $48 | $34.98 | +37.22% | 8 | May 23, 2024 | |
| ANNX Annexon | Maintains: Overweight | $12 → $10 | $4.57 | +119.06% | 3 | May 15, 2024 | |
| CCCC C4 Therapeutics | Maintains: Equal-Weight | $7 → $8 | $4.52 | +76.99% | 4 | May 9, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $63 → $60 | $24.85 | +141.45% | 4 | May 9, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $14 → $12 | $8.40 | +42.86% | 3 | May 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $260 → $262 | $136.27 | +92.27% | 10 | May 3, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $53 → $52 | $42.34 | +22.82% | 4 | Apr 18, 2024 | |
| ANAB AnaptysBio | Initiates: Overweight | $56 | $23.94 | +133.92% | 1 | Apr 11, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $34 → $35 | $7.39 | +373.61% | 5 | Mar 22, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $11 → $13 | $4.12 | +215.53% | 2 | Mar 21, 2024 | |
| MOR MorphoSys AG | Downgrades: Equal-Weight | $17 → $18 | $18.10 | +0.83% | 4 | Mar 14, 2024 | |
| VTYX Ventyx Biosciences | Upgrades: Overweight | $7 → $16 | $2.14 | +647.66% | 3 | Mar 12, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $23 → $20 | $18.93 | +5.65% | 4 | Feb 16, 2024 | |
| KYMR Kymera Therapeutics | Downgrades: Equal-Weight | $26 | $30.22 | -13.96% | 5 | Dec 19, 2023 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $86 → $115 | $110.36 | +4.20% | 7 | Dec 19, 2023 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $4 → $2 | $0.57 | +250.88% | 8 | Nov 14, 2023 | |
| CLDX Celldex Therapeutics | Upgrades: Equal-Weight | $27 | $37.01 | -27.05% | 2 | Nov 10, 2023 | |
| IMVT Immunovant | Maintains: Overweight | $33 → $48 | $26.52 | +81.00% | 8 | Sep 27, 2023 | |
| MORF Morphic Holding | Maintains: Overweight | $67 → $80 | $31.28 | +155.75% | 5 | Apr 25, 2023 | |
| EXEL Exelixis | Initiates: Overweight | $23 | $22.15 | +3.84% | 1 | Mar 9, 2023 | |
| INCY Incyte | Maintains: Equal-Weight | $72 → $75 | $59.02 | +27.08% | 3 | Jan 3, 2023 | |
| GLUE Monte Rosa Therapeutics | Upgrades: Overweight | $19 | $3.59 | +429.25% | 2 | Jan 3, 2023 | |
| ESPR Esperion Therapeutics | Downgrades: Hold | n/a | $2.34 | - | 1 | May 5, 2021 | |
| LUMO Lumos Pharma | Upgrades: Buy | n/a | $2.27 | - | 1 | Mar 11, 2021 | |
| IVA Inventiva | Initiates: Buy | n/a | $2.85 | - | 1 | Aug 4, 2020 | |
| GNFT Genfit | Upgrades: Buy | n/a | $3.97 | - | 1 | Jul 23, 2020 | |
| GLPG Galapagos NV | Downgrades: Hold | n/a | $25.34 | - | 1 | Jul 10, 2020 | |
| OKE ONEOK | Reiterates: Buy | n/a | $82.33 | - | 1 | Apr 15, 2020 | |
| AMRN Amarin Corporation | Maintains: Hold | n/a | $0.71 | - | 2 | Mar 31, 2020 | |
| DBVT DBV Technologies | Downgrades: Hold | $36 → $12 | $0.77 | +1,454.61% | 3 | Mar 17, 2020 | |
| VNDA Vanda Pharmaceuticals | Downgrades: Perform | n/a | $5.27 | - | 4 | Dec 11, 2018 | |
| HRTX Heron Therapeutics | Maintains: Outperform | n/a | $2.74 | - | 2 | Jun 22, 2018 | |
| URGN UroGen Pharma | Maintains: Outperform | n/a | $15.14 | - | 1 | Nov 15, 2017 | |
| PRGO Perrigo Company | Initiates: Outperform | n/a | $25.99 | - | 1 | Sep 7, 2017 | |
| PCRX Pacira BioSciences | Initiates: Market Perform | n/a | $22.74 | - | 1 | Sep 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Perform | n/a | $16.55 | - | 1 | Aug 3, 2017 |
argenx SE
Jun 24, 2024
Maintains: Overweight
Price Target: $478 → $542
Current: $435.49
Upside: +24.46%
Zentalis Pharmaceuticals
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29 → $9
Current: $3.57
Upside: +152.10%
Apellis Pharmaceuticals
May 23, 2024
Maintains: Equal-Weight
Price Target: $57 → $48
Current: $34.98
Upside: +37.22%
Annexon
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $4.57
Upside: +119.06%
C4 Therapeutics
May 9, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $4.52
Upside: +76.99%
Arvinas
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $24.85
Upside: +141.45%
Zymeworks
May 3, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $8.40
Upside: +42.86%
Ascendis Pharma
May 3, 2024
Maintains: Overweight
Price Target: $260 → $262
Current: $136.27
Upside: +92.27%
Rhythm Pharmaceuticals
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $42.34
Upside: +22.82%
AnaptysBio
Apr 11, 2024
Initiates: Overweight
Price Target: $56
Current: $23.94
Upside: +133.92%
Cabaletta Bio
Mar 22, 2024
Maintains: Overweight
Price Target: $34 → $35
Current: $7.39
Upside: +373.61%
Acelyrin
Mar 21, 2024
Maintains: Equal-Weight
Price Target: $11 → $13
Current: $4.12
Upside: +215.53%
MorphoSys AG
Mar 14, 2024
Downgrades: Equal-Weight
Price Target: $17 → $18
Current: $18.10
Upside: +0.83%
Ventyx Biosciences
Mar 12, 2024
Upgrades: Overweight
Price Target: $7 → $16
Current: $2.14
Upside: +647.66%
Nurix Therapeutics
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $18.93
Upside: +5.65%
Kymera Therapeutics
Dec 19, 2023
Downgrades: Equal-Weight
Price Target: $26
Current: $30.22
Upside: -13.96%
Blueprint Medicines
Dec 19, 2023
Maintains: Overweight
Price Target: $86 → $115
Current: $110.36
Upside: +4.20%
Kezar Life Sciences
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $0.57
Upside: +250.88%
Celldex Therapeutics
Nov 10, 2023
Upgrades: Equal-Weight
Price Target: $27
Current: $37.01
Upside: -27.05%
Immunovant
Sep 27, 2023
Maintains: Overweight
Price Target: $33 → $48
Current: $26.52
Upside: +81.00%
Morphic Holding
Apr 25, 2023
Maintains: Overweight
Price Target: $67 → $80
Current: $31.28
Upside: +155.75%
Exelixis
Mar 9, 2023
Initiates: Overweight
Price Target: $23
Current: $22.15
Upside: +3.84%
Incyte
Jan 3, 2023
Maintains: Equal-Weight
Price Target: $72 → $75
Current: $59.02
Upside: +27.08%
Monte Rosa Therapeutics
Jan 3, 2023
Upgrades: Overweight
Price Target: $19
Current: $3.59
Upside: +429.25%
Esperion Therapeutics
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.34
Upside: -
Lumos Pharma
Mar 11, 2021
Upgrades: Buy
Price Target: n/a
Current: $2.27
Upside: -
Inventiva
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $2.85
Upside: -
Genfit
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.97
Upside: -
Galapagos NV
Jul 10, 2020
Downgrades: Hold
Price Target: n/a
Current: $25.34
Upside: -
ONEOK
Apr 15, 2020
Reiterates: Buy
Price Target: n/a
Current: $82.33
Upside: -
Amarin Corporation
Mar 31, 2020
Maintains: Hold
Price Target: n/a
Current: $0.71
Upside: -
DBV Technologies
Mar 17, 2020
Downgrades: Hold
Price Target: $36 → $12
Current: $0.77
Upside: +1,454.61%
Vanda Pharmaceuticals
Dec 11, 2018
Downgrades: Perform
Price Target: n/a
Current: $5.27
Upside: -
Heron Therapeutics
Jun 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $2.74
Upside: -
UroGen Pharma
Nov 15, 2017
Maintains: Outperform
Price Target: n/a
Current: $15.14
Upside: -
Perrigo Company
Sep 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $25.99
Upside: -
Pacira BioSciences
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $22.74
Upside: -
Teva Pharmaceutical
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.55
Upside: -